Cleveland Clinic allies with MedStar
Month: June 2011
Feature: Healthcare sector 2011
“This is a time for great opportunities to develop novel diagnostic tools, therapeutic agents and medical devices for unmet patients’ needs, and that a diversified, multidisciplinary team is a must to develop these opportunities.”
Innovative regions: UK
London’s global appeal as a cultural centre with relative tolerance, combined with its research base across the Golden Triangle, gives it access to scientific and entrepreneurial talent to capitalise on the combination of complicated technology with soft-information skills from media and other services.
Banks double up on IPOs
Banks maintain historical rates to invest in private comapnies and then advise on their flotations.
Cleveland finds its Rainbow
Rainbow Medical will offer Cleveland Clinic early-stage products and concepts for testing by the hospital’s staff, according to news provider Globes.
Geisinger backs Cernostics
Alongside Geisinger’s corporate venturing unit in the round were venture capital firms Novitas Capital and the Pittsburgh Life Science Greenhouse.
SymBio Pharma finds Cephalon
US-based drugs company Cephalon has co-led the Y2bn ($24m) series E round for SymBio Pharmaceuticals, a Japan-based company treating blood disorders.
Cephalon starts venturing fund
Grebow left Cephalon to manage Cephalon Ventures from his eponymous consulting company, according to news provider In Vivo that first spotted the story.
Healthrageous off to $6m start
Partners Healthcare, a US-based medical services provider, has spun off Hop Skip Connect, which has been renamed Healthrageous and raised $6m from venture capital firms North Bridge Venture Partners, Egan Managed Capital and Long River Ventures.
NovaQuest spins off from Quintiles
News provider In Vivo, which spotted the move to independence by NovaQuest, said a regulatory filing by the investment team showed it had raised $117m of a planned $500m fund.
KP moves quickly for Agile deal
Kaiser Permanente Ventures, the corporate venturing unit of the US’s largest health care system, has joined the consortium investing $45m in the series B round for Agile Therapeutics, which is making a contraceptive patch for women.
KP cleans up with Xanitos
Xanitos’ regulatory filing said it had raised $5.1m of a planned $10m round from 13 investors.
Takeda meets its Fate
Takeda Ventures joins peers Astellas Venture Management, Genzyme Ventures and a third, unnamed corporate venturing group as strategic investor in Fate.
Proteostasis treats with Elan
As well as its 24% equity stake, Elan will have a seat on Proteostasis’ board of directors and scientific advisory board, and the first right to exclusively license new drug compounds from the collaboration.